Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.47 |
| ▸ | CDK4 | P11802 | 6/20 | 0.47 |
| ▸ | CCND1 | P24385 | 6/20 | 0.47 |
| ▸ | CDK1 | P06493 | 3/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 5/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.41 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16823266 | 1.00 | CDK2 (0.47) | CDK2CDK4CCND1CDK1CCNB1 | |
| SCHEMBL16515322 | 0.91 | SYK (0.46) | CDK2CDK4CCND1CDK1CCNB1 | |
| SCHEMBL29847788 | 0.91 | SYK (0.46) | CDK2CDK4CCND1CDK1CCNB1 | |
| SCHEMBL31679045 | 0.91 | ACVR1 (0.45) | CDK2CDK4CCND1CDK1CCNB1 | |
| SCHEMBL16514675 | 0.91 | ACVR1 (0.45) | CDK2CDK4CCND1CDK1CCNB1 | |
| SCHEMBL31679059 | 0.90 | CDK2 (0.49) | CDK2CDK4CCND1CDK1CCNB1 | |
| SCHEMBL16514530 | 0.90 | CDK2 (0.49) | CDK2CDK4CCND1CDK1CCNB1 | |
| SCHEMBL16514044 | 0.89 | JAK2 (0.51) | CDK2CDK4CCND1CDK1CCNB1 | |
| SCHEMBL29847745 | 0.89 | JAK2 (0.51) | CDK2CDK4CCND1CDK1CCNB1 | |
| SCHEMBL16514184 | 0.86 | CDK2 (0.46) | CDK2CDK4CCND1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | CDK2 35/4885CDK4 156/4885CCND1 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.